Microsampling for Therapeutic Drug Monitoring of Oral Oncolytics in Oncology Patients

Recruiting now · Not applicable

Conditions studied: Drug Monitoring

In brief

The aim of the study is to perform a clinical validation of the analytical method for dried blood spot microsampling of cabozantinib, pazopanib, sunitinib, lenvatinib, imatinib, abiraterone, enzalutamide, nivolumab, ipilimumab, pembrolizumab, atezolizumab, bevacizumab or enfortumab vedotin. The secondary objective is to test the feasibility of home monitoring (microsampling TDM) of cabozantinib, pazopanib, sunitinib, lenvatinib, imatinib, abiraterone, enzalutamide, nivolumab, ipilimumab, pembrolizumab, atezolizumab, bevacizumab or enfortumab vedotin in oncology patients.

Key facts

Study ID

NCT06545292

Run by

Leiden University Medical Center

People needed

360

Starts

2025-10-06

Expected to finish

2028-07-01

Last updated by the study team

2025-11-21

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Willing and able to provide informed consent;
• 18 years of age or older;
• Using one or more of the following drugs: Cabozantinib, Pazopanib, Sunitinib, Lenvatinib, Imatinib, Abiraterone, Enzalutamide, Nivolumab, Ipilimumab, Pembrolizumab, Atezolizumab, Bevacizumab or Enfortumab vedotin

You may not qualify if…

• Not able to sample themselves using a finger prick

Where it is running

• Leiden University Medical Center — Leiden, South Holland, Netherlands (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.